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The aim of this paper is to explore open innovation (OI) implementation and its impact 
on firm innovation performance in sectors experiencing technological discontinuities. The 
paper employs the framework of inbound, outbound and coupled OI to identify processes 
reflecting sourcing, externalising and exchanging knowledge across organisational bounda-
ries on upstream and downstream innovation activities and explores their impact on the 
innovation performance of new and established technology firms. The empirical setting is 
the UK bio-pharmaceuticals sector during 1991 and 2001, a paradigmatic era of discon-
tinous change and intensified OI implementation. First, our findings show that new tech-
nology firms (NTFs) and established technology firms (ETFs) differ in their extent and 
patterns of inbound, outbound and coupled OI, reflecting that they implement OI to man-
age their competences in light of technological change. Second, we identify a complex and 
multifaceted relationship between OI and patenting performance, with NTFs experiencing 
enhanced performance from some OI processes while ETFs experiencing challenges. The 
paper suggests that delineating OI into inbound, outbound and coupled, along upstream 
and downstream activities, offers a deeper understanding of the role of OI in innovation, 
guiding selective implementation in pursuing enhanced innovation performance during 
periods of discontinuous technological change.
1.  Introduction
External actors make an important contribu-tion to firm innovation and open innovation 
(OI) offers a means for theorising, analysing and 
exploring the impact of various firm practices to 
link internal and external ideas, knowledge and 
resources (Chesbrough, 2006; Chesbrough et al., 
2008; Dahlander and Gann, 2010; Huizingh, 2011; 
West and Bogers, 2014). Open innovation is: ‘…
both a set of practices for profiting from innovation, 
and also a cognitive model for creating, interpreting 
and researching those practices’ (Chesbrough, 2006, 
p. 286) and offers a comprehensive framework that 
captures organisational efforts to attract external 
knowledge and to use internal knowledge externally 
(Chesbrough et al., 2008).
The aim of this paper is to analyse how both 
new and established (or incumbent) technology 
firms (hereafter NTFs and ETFs, respectively, see: 
Rothaermel and Boeker, 2008) in sectors experi-
encing discontinuous change implement OI and 
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how in turn it affects their innovation performance. 
Technological change can be competence enhanc-
ing/destroying (Tushman and Anderson, 1986) 
and it can affect the core and the complementary 
knowledge (Teece 1986, 1992). To analyse how 
NTFs and ETFs implement OI and the implications 
on innovation performance we develop hypothe-
ses on the impact of sourcing (inbound OI), exter-
nalising (outbound OI) and exchanging (coupled 
OI) (Gassmann and Enkel, 2004) knowledge on 
upstream and downstream innovation activities 
(Bianchi et al., 2011, 2014). The bio-pharmaceu-
ticals sector is an apposite setting because during 
the 1990s there is extensive use of collaborative 
R&D and alliances for technology sourcing and 
commercialisation (Cainarca et al., 1992), a clear 
identification of upstream and downstream activ-
ities and of NTFs and ETFs (Rothaermel, 2001a, 
2001b; Rothaermel and Boeker, 2008; Hopkins et 
al., 2013; Dutta and Hora, 2017; Birkinshaw et al., 
2018). The paper contributes to existing debates on 
OI and innovation performance by: first, extending 
existing research on the role of OI in organising 
innovation, the exploitation of new technologies 
and adaptation of ETFs to discontinuous techno-
logical change (West et al., 2008; Dahlander and 
Gann, 2010; Huizingh, 2011; West et al., 2014); 
second, developing a set of hypotheses that can 
guide research in other sectors undergoing tech-
nological change that share similarities to biotech-
nologies (Eggers and Francis Park, 2018); third, 
by employing the comprehensive framework of 
inbound, outbound and coupled OI (Gassmann and 
Enkel, 2004) and operationalising OI with a prac-
tice-oriented approach (Huizingh, 2011; Alexy et 
al., 2016; Zobel et al., 2016) it offers a compre-
hensive, longitudinal exploration of OI (Dahlander 
and Gann, 2010; Huizingh, 2011; West et al., 2014) 
which complements existing research focusing on 
inbound OI (West and Bogers, 2014).
The remainder of the paper is structured as 
follows: Section 2 provides the background to 
this work by discussing existing research on dis-
continuous technological change, collaboration 
and innovation performance of NTFs and ETFs 
in the context of the bio-pharmaceuticals sector. 
Section  3 discusses inbound, outbound and cou-
pled OI on upstream and downstream innovation 
activities and develops hypotheses on their role in 
the innovation performance of NTFs and ETFs. 
Section 4 provides information on the sample and 
data sources and Section 5 discusses empirical con-
structs. Section 6 presents methods and results and 
Section 7 discusses the findings and concludes the 
paper.
2.  Discontinuous technological change, 
collaboration and innovation in the 
bio-pharmaceuticals sector
Technological discontinuities influence the value 
of resources underpinning established production 
and innovation processes (Tushman and Anderson, 
1986). Technological change brings in industrial 
change, with new technology firms, exploiting and 
commercialising the new technology entering estab-
lished sectors and established firms responding by 
reconfiguring resources and capabilities to bridge the 
gap between existing and new value maximising con-
figurations (Lavie, 2006; Eggers and Francis Park, 
2018). The majority of research focuses on techno-
logical change that challenges core/upstream (R&D 
based) knowledge rather than complementary/down-
stream capabilities (e.g. manufacturing, marketing, 
product development) (Teece 1986, 1992; Cozzolino 
and Rothaermel, 2018). Under such conditions, NTFs 
and ETFs can mutually benefit from collaboration 
by leveraging new upstream knowledge and down-
stream competencies, respectively (Rothaermel, 
2001a, 2001b; Cozzolino and Rothaermel, 2018).
Biotechnologies extended the scientific paradigm 
underpinning pharmaceuticals, and while challenged 
upstream-core capabilities in product discovery, 
reinforced the value of competences around comple-
mentary/downstream activities. Other characteristics 
of biotechnologies are high commercial uncertainty 
(Hopkins et al., 2013), long era of ferment (Eggers 
and Francis Park, 2018) and long gestation periods 
due to the stringent regulations in pharmaceuticals. 
Most research on the role of alliances in innova-
tion in the bio-pharmaceuticals sector, focuses on 
alliances for technology commercialisation, where 
NTFs and ETFs combine their complementary com-
petences in new product discovery and development 
(Rothaermel, 2001a, 2001b; Rothaermel and Boeker, 
2008). In such alliances, the division of labour is 
facilitated by a strong appropriability regime and 
IP protection provides a framework for technology 
sharing and openness (Arora and Gambardella, 2010; 
Cozzolino and Rothaermel, 2018).
Research in the US bio-pharmaceuticals sectors 
shows ETFs to enhance their NPD and financial 
performance when they form alliances with NTFs 
to acquire new core knowledge on product discov-
ery, while leveraging their complementary resources 
(Rothaermel, 2001a). US ETFs in bio-pharmaceuti-
cals focus most of their alliances on leveraging com-
plementary competencies, rather than on acquiring 
upstream knowledge; the former type of alliances 
exhibits a higher impact on NPD performance than 
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the later (Rothaermel, 2001b). The relationship 
between the aggregate number of alliances formed 
by ETFs and their NPD performance is curvilin-
ear, reflecting potential inefficiencies in managing 
an increasing number of alliances (Rothaermel, 
2001b). NTFs in the US bio-pharmaceuticals sector 
enhance their innovation performance (both patents 
and NPD) from alliances exploiting their core tech-
nologies (Shan et al., 1994; Fernald et al., 2015) and 
upstream alliances with universities (Dutta and Hora, 
2017). Similar to ETFs, diminishing returns are iden-
tified between the overall alliance activity of NTFs 
and their NPD performance (Deeds and Hill, 1996; 
Rothaermel and Deeds, 2006).
This literature demonstrates a fragmented view 
on the role of openness in the innovation perfor-
mance of NTFs and ETFs. This paper aims to offer 
a comprehensive exploration of OI implementation 
by examining the role of sourcing, externalising and 
exchanging knowledge and resources across organi-
sational boundaries in the innovation performance of 
both NTFs and ETFs.
3.  Inbound, outbound and coupled open 
innovation: hypotheses development
Gassmann and Enkel (2004) developed a framework 
to systematically explore OI by delineating three core 
processes: inbound (outside-in), outbound (inside-
out) and coupled. They can be pursued through 
various informal practices and formal collaborative 
agreements. Inbound OI captures practices, such as 
licensing and technology acquisition, that enrich a 
firm’s knowledge base by accessing and internalising 
ideas and knowledge from external sources, such as 
universities and users (Gassmann and Enkel, 2004). 
Outbound OI includes practices that channel, exploit 
and commercialise internal ideas and technologies 
externally in different markets and with different 
partners, such as licensing out and selling intellec-
tual property (Gassmann and Enkel, 2004; Grant 
and Baden-Fuller, 2004; Arora and Gambardella, 
2010). Coupled OI links inbound and outbound OI in 
knowledge and resource exchange agreements, such 
as cross-licensing, joint research, product develop-
ment and commercialisation, joint manufacturing, 
co-marketing and joint ventures (Gassmann and 
Enkel, 2004).
Existing research on OI focuses on technology 
sourcing, or inbound-upstream OI, but firms can 
also internalise, outsource, buy-in, sell-out and 
cooperate with external actors along downstream 
activities (Vanhaverbeke and Cloodt, 2008; West 
et al., 2008, 2014; Chesbrough and Chen, 2013; 
Chesbrough et al., 2014; Stanko et al., 2017). 
Downstream activities can be outsourced to spe-
cialist service providers; outsourcing clinical trials 
to specialist organisations facilitates time efficiency 
and effectiveness (Gassmann et al., 2008; Howells 
et al., 2008). In new drug development upstream 
and downstream activities can be clearly identi-
fied: drug ‘discovery’ (upstream), encompassing 
target identification and lead optimisation and drug 
‘development’ (downstream), entailing pre-clini-
cal and clinical tests and post- approval activities, 
such as manufacturing, marketing and distribution 
(Arora and Gambardella, 2010; Bianchi et al., 2011; 
Cozzolino and Rothaermel, 2018).
3.1  Inbound open innovation and firm 
innovation performance
Inbound OI refers to internalising ideas, technolo-
gies and expertise that complement and supplement a 
firm’s knowledge base, involving linking with exter-
nal actors and organisations which are at a compara-
tive advantage. Inbound OI may lower the risks and 
costs of exploring emerging technologies, enhancing 
firm flexibility, time to market and NPD performance 
(Leone and Reichstein, 2012; Wang et al., 2012). It 
can be used to internalise pre-competitive research 
from universities, in-license technologies protected 
by intellectual property and other proprietary produc-
tion methods and to access specialist or geograph-
ically distant knowledge. Upstream inbound OI is 
particularly relevant in high-tech sectors experienc-
ing high technical and scientific churn, as firms face 
higher pressure to keep abreast of external develop-
ments. Inbound OI requires searching and evaluating 
suitable partners, investing in processes for knowl-
edge transfer, knowledge matching and project man-
agement (Lakemond et al., 2016), in diffusing and 
storing external knowledge and re-adjusting internal 
practices (Lavie, 2006).
With inbound OI firms can access downstream 
competences to complement existing activities (e.g. 
Dutta and Hora, 2017), improving performance 
through economies of scale and scope, achieving 
efficiencies and reducing costs by soliciting user 
feedback in new product development, trials and cus-
tomisation (Dahlander and Gann, 2010). ETFs can 
benefit from such scale economies and efficiencies, 
while NTFs, as they are less likely to be vertically 
integrated, can benefit from accessing complemen-
tary downstream competences (Rothaermel and 
Deeds, 2004; Dutta and Hora, 2017). ETFs with a 
broad knowledge base are expected to enhance their 
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innovation performance by both upstream and down-
stream inbound OI (Rothaermel, 2001a, 2001b). For 
ETFs facing technological discontinuities that chal-
lenge core knowledge, upstream inbound OI will 
have a bigger impact on innovation performance than 
downstream inbound OI (Eggers and Francis Park, 
2018). Following existing research we propose that 
upstream and downstream inbound OI can comple-
ment the narrow expertise of NTFs enhancing their 
innovation performance (Khilji et al., 2006; Fernald 
et al., 2015; Dutta and Hora, 2017); the impact will 
be stronger for downstream inbound OI as engaging 
in further product development and commerciali-
sation encourages learning that is underdeveloped 
internally. The following hypotheses are proposed:
H1a: Intensifying upstream and downstream inbound 
open innovation processes positively affects the inno-
vation performance of new technology firms; down-
stream inbound open innovation has a bigger effect 
than upstream.
H1b: Intensifying upstream and downstream inbound 
open innovation processes positively affects the inno-
vation performance of established technology firms; 
upstream inbound open innovation has a bigger ef-
fect than downstream.
3.2  Outbound open innovation and firm 
innovation performance
Outbound OI captures knowledge outflows from 
a firm’s innovation process and includes all sys-
tematic activities aimed at exploiting firm-spe-
cific knowledge and resources, and products and 
services stemming from intermediate NPD stages 
(Gassmann and Enkel, 2004; Dahlander and Gann, 
2010). Outbound OI can improve time to market, 
facilitate the diffusion of technologies influencing 
industry standards (Dahlander and Gann, 2010). 
Participating in external markets for technol-
ogy provides a stream of profits, helps to timely 
recoup investments in R&D and to efficiently man-
age IP portfolios by benefiting from marginal and 
peripheral technologies (Arora and Gambardella, 
2010; Natalicchio et al., 2014). Pursuing outbound 
OI is challenging due to the intangible nature of 
knowledge, imperfections in evaluating ex ante its 
future value, the need to identify suitable partners 
and the higher risks of opportunism and increased 
future competition (Arora and Gambardella, 2010; 
Natalicchio et al., 2014). Exploiting technologies 
both internally and through licensing, can have a 
negative impact on profit margins, due to costs asso-
ciated with the need for close coordination to avoid 
cannibalisation and safeguard against increased 
future competition from licensees (Bianchi et al., 
2014). Licensing out is not free from disadvan-
tages, especially when licensing across different 
industries, as it can divert a firm’s focus outside 
its core product and customer base, diluting its 
attention and potentially harming long-term inno-
vation performance (Leone and Reichstein, 2012). 
Particularly for technologies distant from the core, 
licensors offer greater support to licensees, as the 
threat of competition from leapfrogging is not 
direct. Often, licensors use grant-back clauses to 
ensure that improvements in licensed technologies 
are transferred back, enabling future appropriation 
and eliminating the threat of direct competition 
(Leone and Reichstein, 2012; Bianchi et al., 2014; 
Laursen et al., 2017). Grant-back clauses can facili-
tate learning and are more likely in licensing agree-
ments of core rather than peripheral technologies 
(Laursen et al., 2017).
NTFs, due to their specialist technological 
expertise and need to recoup investments in R&D 
are likely to pursue upstream outbound OI to 
exploit their core technologies in different applica-
tions. Due to the liability of newness (Rothaermel 
and Boeker, 2008), NTFs are less powerful in 
negotiating learning from licensing out and the 
rise of future competition can negatively affect 
their inventiveness in the long run. ETFs with 
upstream outbound OI can effectively manage their 
technology portfolio, benefiting from exploiting 
peripheral and underutilised technologies; because 
grant-back clauses are less likely when licensing 
non-core technologies, we expect upstream out-
bound OI to have a less pronounced effect on their 
innovation performance compared to downstream. 
With outbound OI firms can leverage unique down-
stream competences, underutilised resources and 
excess production capacity, enhancing flexibility 
and efficiency, positively influencing innovation 
performance and competitiveness. Leveraging 
complementary downstream capabilities in alli-
ances provides ETFs with wider access to new 
markets enhancing both their NPD and financial 
performance (Rothaermel 2001a, 2001b). NTFs 
in biotech leverage downstream capabilities with 
outbound OI when providing specialist services 
related to clinical trials (Bianchi et al., 2011). The 
above lead to the following hypotheses:
H2a: Intensifying upstream and downstream out-
bound open innovation processes enhances the 
innovation performance of new technology firms; up-
stream outbound open innovation has a bigger effect 
than downstream.
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H2b: Intensifying upstream and downstream out-
bound open innovation processes has a positive ef-
fect on the innovation performance of established 
technology firms; downstream outbound open inno-
vation has a bigger effect than upstream.
3.3  Coupled open innovation and firm 
innovation performance
Coupled OI captures knowledge and resources 
exchange and sharing, the co-occurrence of inbound 
and outbound OI (Gassmann and Enkel, 2004; Enkel 
et al., 2009; West and Bogers, 2014) and co-creation 
with external actors (Piller and West, 2014; West et 
al., 2014). Firms are likely to use coupled OI to coor-
dinate distributed, complex and overlapping tasks, 
to share the risks and costs of uncertainty in joint 
research, creating value by sharing complementary 
and supplementary resources. In coupled OI, part-
ners are likely to experience high degrees of recipro-
cal interdependence, which requires close interaction 
and communication to manage complexity in coor-
dinating joint tasks. Both partners have incentives to 
invest in both relationship specific assets and knowl-
edge sharing routines to enhance joint value creation 
(Dyer and Singh, 1998; Dyer et al., 2018). The ability 
of partners to capture a portion of the common value 
created in such agreements depends on their bargain-
ing power (Dyer et al., 2008, 2018). Partner ex ante 
bargaining power depends on the scarcity and value 
of resources that they contribute to the agreement, 
with the partner making the most critical contribution 
being more likely to appropriate a higher share of the 
common value (Dyer et al., 2008).
Investments in relationship specific assets and 
knowledge sharing routines dynamically co-evolve 
increasing the potential common value. Such invest-
ments may not be easily re-deployable which cre-
ates appropriation concerns, motivating partners to 
intensify investments in value capture mechanisms 
(Dyer et al., 2018). Partners with greater technolog-
ical experience and a larger internal resource base, 
which creates opportunities for private value cre-
ation from alliances (Dyer et al., 2008), make higher 
investments in value capture mechanisms and often 
use power-seeking tactics (Arora and Gambardella, 
2010; Panico, 2017). We expect that due to their 
larger resource base, ETFs will be more likely to 
have control over a greater set of resources and as 
a result to enjoy a better negotiating position and 
higher bargaining power, enabling potential capture 
of greater value in alliances (Rothaermel, 2001a, 
2001b). NTFs with a focused range of competences 
and resources are likely to have control over a narrow 
set of resources and because of their liability of new-
ness, to suffer from weaker negotiating and bargain-
ing power. Relative bargaining power in alliances is 
influenced by the criticality of resources that firms 
contribute to the agreement. Due to the characteris-
tics of biotech and its impact on core and comple-
mentary competences, we expect that, overall, NTF 
bargaining power will be stronger in upstream cou-
pled OI agreements compared to downstream, while 
the reverse will be the case for ETFs. It should be 
noted that the criticality of resource contributions, 
at firm-level, may be difficult to be judged ex ante, 
especially when such resources involve knowledge 
and techniques related to emerging technologies of 
uncertain commercial potential (e.g. Hopkins et al., 
2007). We formulate the following hypotheses:
H3a: There is a negative relationship between in-
tensifying upstream and downstream coupled open 
innovation processes and innovation performance 
for new technology firms; this impact is more pro-
nounced for downstream compared to upstream cou-
pled OI.
H3b: There is a positive relationship between up-
stream and downstream coupled OI and innovation 
performance for established technology firms; this 
impact is more pronounced for downstream com-
pared to upstream coupled OI.
Table 1 provides an overview of our hypotheses.
4.  Sample and data sources
To identify the population of firms in the UK 
bio-pharmaceuticals sector we consulted two 
consecutive editions (2000 and 2002) of the UK 
Biotechnology Directory (Coombs and Alston, 2000, 
2002), and extended this list with information from 
membership to the UK Bio-Industry Association. 
The 1980s marked the first decade of NTF entry 
in UK bio-pharmaceuticals, as the scientific para-
digm in pharmaceuticals embraced biotechnologies 
(Orsenigo, 1989; Howells et al., 2008), with a suc-
cessive wave of higher NTF entry during the 1990s, 
associated to a more supportive environment due 
to institutional changes in both drug regulation and 
finance (Hopkins et al., 2013). The turn to 2000s is 
not only characterised by a significant shift in finance 
supporting start-ups in biotech, but the entire decade 
witnessed consolidation, with ETFs merging with 
other ETFs and acquiring NTFs (Gottinger, 2010; 
Hopkins et al., 2013; Cozzolino and Rothaermel, 
2018). For the purposes of this study, we focus on 
the period between 1991 and 2001, as there is a 
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clear identification of NTFs and ETFs, an upsurge 
in OI activity (Hagedoorn and Roijakkers, 2006) 
and a gradual internalisation of biotechnologies by 
ETFs through collaboration (Hopkins et al., 2007; 
Birkinshaw et al., 2018). The commercial potential 
of biotechnologies started becoming clearer post 
2000s (Hopkins et al., 2007; Birkinshaw et al., 2018); 
collaborating for R&D and technology sharing are 
common during early stage development of other 
technologies (Cainarca et al., 1992) which broadens 
the impact of the insights drawn from studying this 
sector during this time period.
We identified 110 UK-based independent firms, 
including the UK subsidiaries of MNEs. As data 
collection was retrospective, we identified all firms 
active in 2003, which may omit firms active during 
1991–2001 that seized operation before 2003. 
Following existing research in this sector (Rothaermel 
and Boeker, 2008) we identify ETFs, firms imprinted 
under technologies prior to biotech, having primary 
SIC codes in Pharmaceuticals (including a few firms 
in Chemicals)1 and NTFs as the dedicated biotechnol-
ogy firms, with core operations in Biotechnology.2
We capture open innovation processes by observ-
ing practices for OI in formal collaborative agreements 
and alliances with independent actors (Chesbrough, 
2006; Hung and Chou, 2013) reported in ReCap and 
BioScan.3 We identified that out of the 110 firms, 66 
ETFs and NTFs formed alliances; 2,077 alliances 
were initiated between 1991 and 2001, with full 
information on content provided for 1,983. Starting 
from 1980s and extending beyond 2000, there is 
considerable variety across ETFs in the extent and 
time period they embraced biotechnologies, if they 
did at all (Birkinshaw et al., 2018). To capture inno-
vation performance, we collected firm-level data on 
patents from the UKPTO, and to explore our hypoth-
eses we use information on company accounts from 
FAME and Thomson’s Analytics, R&D investments 
from Thomson’s Analytics and the UK DTI’s R&D 
Scoreboard.
5.  Data analysis and variables
5.1  Inbound, outbound and coupled open 
innovation processes in collaborative 
agreements
To operationalise OI we adopt a practice-oriented 
approach (Alexy et al., 2016) and identify inbound, 
outbound and coupled OI based on the content of 
collaborative agreements as provided by ReCap and 
BioScan. Analysis of content is an emerging research 
practice, leading to rich information, enabling a com-
prehensive exploration of the relationship between 
OI and firm innovation performance (Huizingh, 
2011; Zobel et al., 2016). We identify the three OI 
processes at both upstream and downstream activities 
(Vanhaverbeke and Cloodt, 2008; Zobel et al., 2016). 
We proceed by allocating each agreement to one of 
the six categories: upstream/downstream inbound, 
outbound and coupled OI. We generate six variables 
for each firm with a value equal to the number of 
agreements under each category and year to capture 
the extent of openness. The allocation focuses on the 
role that the firm in our sample assumes in the agree-
ment (e.g. licensee vs licensor) and uses information 
on both its type (i.e. licensing, cross-licensing and so 
on) and description (e.g. testing a protein sequence, 
clinical trials and so on). A sample of the allocated 
agreements was shared with a biologist to discuss 
and check the coding process. To avoid inaccurate 
allocations, we removed agreements with incomplete 
content.
5.2  Remaining variables
5.2.1  Firm innovation performance
Patents are an effective measure of innovation per-
formance in science-based sectors (e.g. Ziedonis, 
2008) and employed widely in literature capturing 
firm innovation from alliances (e.g. Deeds and Hill, 
1996; Sampson, 2007). We collect patent data from 
Table 1. Overview of hypotheses for the role of inbound, 
outbound and coupled OI on NTF and ETF innovation 
performance in the bio-pharmaceuticals sector
Open innova-
tion processes
New technol-
ogy firms
Established technol-
ogy firms
Inbound
Upstream Hypothesis 1a Hypothesis 1b
Positive Positive (bigger than 
downstream)
Downstream Positive (big-
ger than 
upstream)
Positive
Outbound
Upstream Hypothesis 2a Hypothesis 2b
Positive (big-
ger than 
downstream)
Positive
Downstream Positive Positive (bigger than 
upstream)
Coupled
Upstream Hypothesis 3a Hypothesis 3b
Negative Positive
Downstream Negative 
(bigger than 
upstream)
Positive (bigger than 
upstream)
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the UK Patent and Trademarks Office (UKPTO) via 
Esp@cenet as we focus on UK-based firms. Patents 
are identified by matching both the name and the 
address of firms in our sample with those of the 
patent assignees (Arora et al., 2011). Multinational 
enterprises may assign patents at the HQ level. 
When the MNE HQ is outside the UK, we examine 
information on inventor location, as it can signal 
the location(s) of invention, and then, moved on 
to assign any patents with UK-based inventors to 
the UK-based subsidiary in our sample. To allocate 
patents over time we use the filling rather than pub-
lication dates as they more closely reflect the time 
of new knowledge creation.
5.2.2  Factors affecting firm innovation  
performance
We collect data on firm-specific characteristics 
influencing innovation performance, such as invest-
ments in R&D and firm size, to account for the 
amount of investments in innovation and resource 
endowments, respectively. Firm size is captured by 
number of employees, as due to the nature of the 
technology and long gestation periods, firms may 
not immediately generate sales (Rothaermel and 
Boeker, 2008; Birkinshaw et al., 2018; Moeen and 
Mitchell, 2020).
5.2.3  Experience in managing collaborative 
agreements
Experience in managing alliances can improve firm 
efficiency in managing collaborative tasks (Anand 
and Khanna, 2000; Wang and Rajagopalan, 2015), 
and could be linked to efficient OI management. 
We measure firm collaborative experience with the 
aggregate number of alliances, considering that on 
average each alliance lasts for 5 years (Kogut, 1988). 
We use 1 year lagged values of this measure to reflect 
that it takes on average 1 year for firms to transfer 
any learning from past experience to current imple-
mentation of OI (Lavie et al., 2011). We use loga-
rithmic transformations due to diminishing returns 
in alliance experience accumulation (e.g. Sampson, 
2005).
6.  Analysis and results
6.1  Analysis
The analysis is based on a panel observing 66 firms 
using biotechnologies between 1991 and 2001, with 
32 ETFs and 34 NTFs. First, we examine statisti-
cal differences across the six OI processes (OIPs), 
exploring whether our analytical constructrs capture 
distinct approaches to OI. A t-test, together with 
bootstrap for robustness (99% confidence interval) 
show statistically significant differences across all 
OIPs.
Table  2 shows average values for all OIPs for 
ETFs and NTFs, respectively. For ETFs, on aver-
age, upstream inbound (2.3) and upstream coupled 
(1.2) are the most frequently used, reflecting a ten-
dency to in-source knowledge around early NPD 
stages. NTFs focus on upstream activities forming 
on average 1 (outbound), close to 0.8 (coupled) and 
0.6 (inbound) OIPs, reflecting that they mainly use 
OI for external knowledge outflows at early drug 
discovery stages, and secondary for knowledge 
exchange or joint creation. Table  2 compares the 
two groups and shows that there are statistically 
significant differences across all OIPs with the 
exceptions of outbound (both upstream and down-
stream). Overall the comparisons show that ETFs 
and NTFs employ different OI processes, reflecting 
differences in their competences and use of OI to 
manage and redeploy them in light of the techno-
logical change.
To examine the role of OIPs on firm innova-
tion performance we carry out regression anal-
yses separately for ETFs and NTFs similar to 
relevant research on firm groups (Vahter et al., 
2014). Table  3 provides correlation coefficients 
and Table 4 presents the results. The panel is con-
siderably unbalanced, mainly due to firm entry 
after 1991, with 20 NTFs being established after 
1995 (this pattern is consistent with Hopkins et 
al., 2013). Since our dependent variable is a count 
variable and due to overdispersion we conclude 
that the Negative Binomial model is better suited4 
to Poisson.5
The Wald Chi2 statistic shows that the interpre-
tative power of the Random Effects (RE) specifica-
tion is significant for ETFs but not for NTFs. We 
examine joint significance for groups of variables 
for NTFs as follows: first, only for controls, sec-
ond, for all OIP variables together, third, only for 
the two OIP variables that appear to be significant 
in the initial model (upstream coupled and down-
stream inbound, see Table  4). Joint significance 
is confirmed only in the third case (Chi2  =  7.61, 
prob  =  0.022) showing a positive and significant 
association between upstream coupled and down-
stream inbound OIPs and NTF innovation perfor-
mance. Results for ETFs show a significant and 
negative association between downstream inbound, 
downstream outbound and innovation perfor-
mance which is counter to our expectations (part of 
hypotheses 1b and 2b). We examine curvilinearity 
but do not find support. Comparisons on the rela-
tive impact of upstream and downstream OIPs are 
© 2020 RADMA and John Wiley & Sons Ltd
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not carried out due to insignificance for one of the 
two variables across models. The following sec-
tions discuss our results for ETFs and NTFs.
6.2.  Open innovation and the innovation 
performance of ETFs
Our results show a significant and negative asso-
ciation between downstream inbound, downstream 
outbound and ETF innovation performance. The 
findings contradict the experiece of US ETFs in 
bio-pharmaceuticals which enhance both NPD and 
financial performance by leveraging downstream 
competences in alliances with NTFs (Rothaermel, 
2001b). The following provide an interpretation of 
why our results differ. ETFs faced high complexi-
ties and costs in integrating biotechnologies with 
existing complementary downstream capabilities 
and the need to invest in supporting organisa-
tional innovations (Hopkins et al., 2007). The use 
of genomics introduced complexitities in clinical 
trials, product approval and development, while 
Hopkins et al. (2007) suggest that from early 1990s 
to early 2000s biotechnologies proved to be less 
successful than anticipated and they mainly focused 
on established targets and treatments contributing 
less to novel therapies than after 2000 (Hopkins 
et al., 2007; Birkinshaw et al., 2018). These may 
provide an explaination for the negative impact we 
observe on patents as they capture novelty.
Our results reflect the difficulties in identifying 
suited technologies under technological uncertainty 
and of integrating unfamiliar external sources of 
knowledge that may be disconnected with existing 
thinking and processes (Lavie, 2006; Hopkins et 
al., 2007; Stanko et al., 2017). They also reflect that 
adapting complementary capabilities to the exploita-
tion of new technologies requires closer coordination 
and communication across their interface, which is 
more effectively organised through tighter coordi-
nation (Moeen and Mitchell, 2020). The negative 
association between downstream outbound and ETF 
innovation performance reflects the barriers in dis-
sentangling and externalising intermediate outputs of 
the NPD process that are interelated with other NPD 
projects. This is particularly the case for ETFs exter-
nalising compounds that are interlinked within thera-
peutic areas (Chesbrough and Chen, 2013).
Broadly our resylts reflect the challenges facing 
ETFs when substituting and transforming embed-
ded capabilities which are interdependent with other 
NPD stages (Lavie, 2006). Furthermore, effective 
Table 2. Comparisons of ETFs and NTFs across upstream and downstream open innovation processes: non-parametric 
tests
Upstream open innovation processes Downstream open innovation processes
Inbound Outbound Coupled Inbound Outbound Coupled
ETFs (N = 208)
Mean 2.3 0.89 1.19 1 0.63 0.53
Median 1 0 0.5 0 0 0
St. Dev. 3.201 1.325 1.980 1.469 1.144 1.067
Min 0 0 0 0 0 0
Max 14 7 11 8 6 7
NTFs (N = 184)
Mean 0.61 1 0.78 0.29 0.53 0.18
Median 0 1 0 0 0 0
St. Dev. 0.873 1.572 10.322 0.619 0.975 0.507
Min 0 0 0 0 0 0
Max 6 10 8 3 5 3
Statistics: Kolmogorov–Smirnov
ETFs 0.254 0.274 0.288 0.285 0.361 0.392
NTFs 0.324 0.288 0.303 0.459 0.392 0.502
Significance 0.000 0.000 0.000 0.000 0.000 0.000
Comparisons
Mann–Whitney (U) 12.933 19.827 17.095 13.838 18.553 15.871
Standardised test 
statistic
−5.895 0.671 −2.004 −5.578 −0.626 −4.020
Significance 0.000 0.502 0.045 0.000 0.532 0.000
© 2020 The Authors. R&D Management published by RADMA and John Wiley & Sons Ltd
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implementation of OI may require reorganising 
internal processess and systems of communication 
to develop absorptive, desorptive and multiplicative 
capabilities, broadening R&D personel skills on OI 
management (Gassmann and Enkel, 2004; Spithoven 
et al., 2011; Bianchi et al., 2015) and the develop-
ment of processes for value creation and capture in 
OI (Chesbrough et al., 2018).
6.3  Open innovation and the innovation 
performance of NTFs
Our results can have important implications for 
NTFs suggesting that innovation performance can 
be enhanced when they simultaneously implement 
upstream coupled and downstream inbound OIPs. 
For instance, this can reflect a combination of agree-
ments for joint research and for internalising external 
expertise on further product development and commer-
cialisation. This is in line with Dutta and Hora (2017) 
showing that when NTFs form exploratory alliances 
to in-source knowledge from universities together 
with alliances for commercialisation with ETFs, they 
enhance both their invention and commercialisation 
performance. Our results echo research showing that 
NTFs which engage in commercialisation alliances 
better understand market needs, which enhances in 
turn their success in patents (Shan et al., 1994; Khilji 
et al., 2006; Fernald et al., 2015). Broadly this reflects 
the need for close coordination between upstream and 
dowsntream activities for effective communication and 
technology commercialisation (Moeen and Mitchell, 
2020). Our results confirm part of hypothesis 1a 
(inbound dowstream OI) and contradict part of hypoth-
esis 3a (coupled upstream). The positive impact of 
coupled upstream OIPs, showing that NTFs overcome 
negotiation and appropriation barriers in such agree-
ments, could be interpreted through the science-base 
nature of biotechnologies and the close links of NTFs 
with universities and publicly funded research, which 
we believe reflect most coupled upstream OI (Orsenigo, 
1989; Hopkins et al., 2013). Overall, NTFs wishing to 
effectively pursue such an OI strategy of linking cou-
pled with inbound OIPs upstream and downstream, 
would need to develop an integrative view across 
absorptive, desorptive and relational capabilities to 
support their simultaneous implementation (Spithoven 
et al., 2011; Chesbrough et al., 2018).
7.  Discussion and conclusions
The paper developes hypotheses on the role of inbound, 
outbound and coupled OI on upstream and downstream 
activities in the innovation performance of ETFs and 
NTFs when technological change challenges upstream 
competences of ETFS. The UK bio-pharmaceuticals 
sector between 1991 and 2001 provides an aposite set-
ting for this exploration. Findings show that, contrary 
to expectations, ETF innovation performance is nega-
tively associated with downstream inbound and out-
bound OI. Results for NTFs support our expectations 
Table 4. Negative binomial panel data model estimates, random effects specification (dependent variable: number of 
patents)
ETFs NTFs
Coefficients Standard errors Coefficients Standard errors
Independent variables
Upstream inbound 0.085 0.099 −0.101 0.282
Upstream outbound 0.164 0.208 0.177 0.201
Upstream coupled 0.034 0.092 0.266** 0.125
Downstream inbound −0.425** 0.188 0.645** 0.330
Downstream outbound −0.720* 0.383 0.243 0.210
Downstream coupled −0.106 0.232 −0.354 0.397
Number of employees 0.000 0.000 0.000 0.001
R&D expenses 0.002 0.002 0.001 0.029
Experience in collaboration −0.338 0.412 0.122 0.350
Constant 0.851 1.328 0.136 1.402
Observations 132 83
Firms 24 20
Wald Chi2 39.04 10.07
Prob > Chi2 0 0.3451
Log Likelihood −108.532 −64.990
Significance levels: *P < 0.1, **P < 0.05, ***P < 0.01.
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that downstream inbound OI enhances innovation, but 
this is only in combination with upstream coupled OI, 
with the latter being positive, contrary to our hypothe-
sis. Our findings are limited to the specific sector and 
time period. Subsequent changes in the sector, led 
to what was initially breakthrough biotechnologies 
becoming integral part of the underpinning scientific 
disciplines, to the close interlacing of ETFs and NTFs, 
with backward and forward integration, respectively, 
by some major firms in the sector driven by the desire 
to capture greater value (Lavie, 2006; Hopkins et al., 
2013; Cozzolino and Rothaermel, 2018). There is firm 
heterogeneity and variety in their paths of evolution 
that should be acknowledged as a limitation of our 
analysis of groups of ETFs and NTFs (e.g. Birkinshaw 
et al., 2018).
Our findings show that a deeper understanding 
is needed on the interplay between internal innova-
tion processes, OI and firm processes to build inter-
nal capabilities and reconfigure competences in light 
of technological change (Lavie, 2006; Eggers and 
Francis Park, 2018). Indeed, our results show, parti-
ciularly for NTFs, the need to understand how firms 
interrelate and manage different OI processes across 
upstream and downstream activities. For ETFs results 
suggest that a deeper exploration is required to under-
stand the range of ineffiencies and costs associated 
with OI, and the nature of capabilities supporting effi-
cient OI implementation and management (Gassmann 
and Enkel, 2004). Identifying and internally develop-
ing upcoming and uncertain external technologies 
challenges ETFs’ innovation performance. So does 
their attempt to externally exploit downstream capa-
bilities in an attempt to reconfigure existing capabil-
ities and achieve greater efficiencies. Deploying and 
reconfiguring downstream capabilities in alliances 
to commercialise externally sourced technologies 
entails challenges stemming from coordinating their 
interface, lowering transaction costs and internalising 
economies of scale. The subsequent (post 2000) back-
ward integration to biotechnologies by most major 
pharmaceuticals firms provides further testament 
to our conjectures (Arora and Gambardella, 2010). 
Our results for both NTFs and ETFs reflect the effi-
ciency and innovation benefits of a close coordination 
between upstream and downstream activities.
The paper is limited to a specific time period and 
sector; however, it shows that deliniating between 
inbound, outbound and coupled OI is instrumental in 
understanding the relationship between OI and firm 
innovation performance, highighting the influential 
role of the Gassmann and Enkel’s (2004) framework 
in guiding effective in-sourcing, externalising and 
exchange of knowledge and resources. Employing the 
OI framework on upstream and downstream activities, 
sheds light on how ETFs and NTFs in sectors experi-
encing technological change can use OI to manage and 
develop their competences. Distinguishing between 
upstream and downstream activities adds to Gassmann 
and Enkel’s (2004) framework, by highlighting that 
OI can make a different impact depending on the 
context of its application; for instance, inbound OI 
appears with a different sign for upstream compared 
to downstream activities for both ETFs and NTFs. Our 
findings are aligned with existing research showing 
that external sourcing strategy depends on the nature 
of competences sources, technical or complementary 
(Moeen and Mitchell, 2020).
Because the period explored is a paradigmatic 
example of how emerging technologies develop 
through OI, our findings can be of relevance for sec-
tors experiencing technological change with similar 
characteristics to biotech, as suggested in Eggers and 
Francis Park (2018). The hypotheses developed in 
this paper and their partial support call for further 
research in sectors similar in nature to the early stages 
of biotechnology development. Future research can 
modify the expectations put forward in this paper, to 
faciliate research on the use and impact of OI on ETF 
and NTF innovation performance when technolog-
ical change unsettles complementary (downstream) 
rather than core ETF knowledge (Cozzolino and 
Rothaermel, 2018).
This paper reinforces the need for future research 
on the OI framework (Gassmann and Enkel, 2004), 
on the barriers to fully benefit from OI (Dahlander 
and Gann, 2010; Stanko et al., 2017) and on the 
processes that enable value creation and capture in 
OI (Chesbrough et al., 2018). The latter is the cor-
nerstones of OI capabilities and envelopes capabil-
ities for new product development, innovation and 
alliance management (Wang & Rajagopalan, 2015; 
Spithoven et al., 2011; Chesbrough et al., 2018).
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Notes
1 Specifically the US SIC codes are: 2833 ‘Medicinal 
Chemicals and Botanical Products’; 2834 ‘Pharmaceutical 
Preparations’; 2835 ‘Diagnostic Substances’; 2836 
‘Biological Products, Except Diagnostic’.
2 Specifically the US SIC code is: 8731 ‘Commercial 
Physical and Biological Research’.
3 ReCap and BioScan are both notable for their scope, 
completeness of information for their consistency and 
reliability and provide information on all types of for-
mal agreements aiming at discovering and developing 
bio-pharmaceutical products, draw on press releases, 
sector specific magazines, US Securities and Exchange 
Commission (SEC) filings, and company annual re-
ports, with information dating back to 1979.
4 STATA estimates the ‘alpha’ parameter for the pulled 
cross-section and time-series dataset, and it is equal to 
5.48 and 1.92 for Pharma and BFs, respectively, sug-
gesting overdispersion in both datasets (LR test values: 
LR = 118.87 and LR = 18.15, respectively, and Prob ≥ 
Chibar2 = 0.000 in both cases).
5 As the fixed effects estimation relies on first-differencing, 
a number of observations were automatically dropped 
as for a number of firms there were no changes in the 
dependent variable over time. Specifically, the total 
number of observations for the fixed effects specifica-
tion is substantially reduced (59 and 41 observations 
for Pharma and BFs generated by nine and eight firms, 
respectively), severely affecting degrees of freedom and 
reliability of estimates. Therefore, Table 4 presents only 
random effects estimates.
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